TXG(10x Genomics, Inc.) 的财务报表:医疗保健,医疗器械。数据来自 SEC 公开申报与市场行情,不构成投资建议。
| 科目 | FY 截至 2021-12-31 | FY 截至 2022-12-31 | FY 截至 2023-12-31 | FY 截至 2024-12-31 | FY 截至 2025-12-31 |
|---|---|---|---|---|---|
| 营业收入 | $490.49M | $516.41M | $618.73M | $610.78M | $642.82M |
| 毛利润 | $416.40M | $396.02M | $409.31M | $414.48M | $443.88M |
| 营业利润 | −$52.25M | −$167.94M | −$265.33M | −$194.56M | −$60.98M |
| 净利润 | −$58.22M | −$166.00M | −$255.10M | −$182.63M | −$43.54M |
| 经营现金流 | −$21.37M | −$33.61M | −$15.20M | $6.66M | $136.05M |
| 自由现金流 | −$122.65M | −$165.27M | −$63.80M | −$5.73M | $130.12M |
| 摊薄每股收益 | $-0.53 | $-1.46 | $-2.18 | $-1.52 | $-0.35 |